07.29.25 -- Exploring Outsourcing's Role In CGT Scalability And Affordability

Optimize your biopharmaceutical technology transfer by prioritizing clear communication, thorough training, and strategic planning to ensure success.

Rapidly shifting modalities require broad CDMO expertise and capacity, and commercializing recombinant vector vaccines requires a skill set that differs from protein or peptide based approaches.

In this conversation, Dr. Boro Dropulić, Executive Director of Caring Cross, shares his perspective on regional challenges, opportunities for innovation, and the role of global partnerships.

CDMOs give therapy developers access to state-of-the-art production platforms and expertise without the massive up-front investment required for in-house manufacturing.

Enhance AAV gene therapy quality and regulatory compliance with our advanced AEX-based purification platform, achieving >90% full capsid purity — even for oversized AAV8 vectors.

Gain insight into how small variations in the apheresis process can lead to significant differences in the cellular products, ultimately influencing therapy effectiveness.

By refining variables such as starting DNA, reagents, cell density, and media composition, organizations can improve rAAV process efficiency and scalability.

Achieving optimized, scalable suspension processes for adeno-associated virus (AAV)-based therapeutics comes with a number of technical and business challenges.

What is actually behind the procurement of a pharmaceutical labeling machine and how does the process work? You can find out here what the path to your pharmaceutical labeling machine looks like.

Discover how advanced plasmid manufacturing and AAVion® platform can drive your AAV program forward by reducing production costs while maximizing efficiency.

Learn the principles of commercialization readiness and guidance to address them in process development as well as the best time to implement automation and minimize commercialization risks.

Find a consistent and comprehensive approach to risk management. Unify all risk-related activities and documents, providing a 360-degree view of your enterprise's risk landscape.

Optimize leukapheresis-derived cell therapies by enhancing the safety, quality, and viability of manufacture-ready cryopreserved leukopaks.

From precise edits to robust expression, get iPSC genome editing done right — from the experienced innovators in gene editing and iPSC technology.